IL10 and enterocolitis: In our here presented preclinical intervention trial, we investigated potential pathogen-lowering, disease-alleviating, and immune-modulatory effects upon peroral treatment of microbiota-depleted IL-10−/− mice suffering from acute C. jejuni-induced enterocolitis with the commercial competitive exclusion product and probiotic compound Aviguard®.